Posted by Michael Wonder on 17 Nov 2022
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
16 November 2022 - Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer.
More than 100 people are set to benefit after NICE published final draft guidance recommending from a new targeted therapy for advanced lung cancer today.
